Streetbeat News

Products Services

TVTX

CSL Vifor and Travere Therapeutics have received conditional marketing authorization from the European Commission for FILSPARI (Sparsentan), the first non-immunosuppressive therapy for IgA Nephropathy (IgAN) in Europe. This approval is based on significant results from the phase-III PROTECT trial.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 7:14 am

TSLA

Tesla Inc's senior executive Lars Moravy announced that 4680 cell production, essential for Cybertruck manufacturing, increased by 18% to 20% in Q1, enabling the production of over 1000 Cybertrucks per week at Giga Texas. Despite previous reports of production challenges, Moravy assured that cell production will stay ahead of Cybertruck demand in Q2, with the company maintaining a cell inventory. However, achieving volume production faces hurdles due to new technologies and supplier limitations. Tesla's annual target of 250,000 Cybertruck deliveries is postponed to 2025.

Portfolio Pulse from Anan Ashraf

April 24, 2024 | 6:59 am

ANPCF

AZN

ANGLE has signed a commercial agreement with AstraZeneca to develop a novel methodology for CTC micronuclei detection, enhancing DNA damage response detection. The development, based on ANGLE's pKAP1 CTC-based DDR assay, will take place over 6 months and is valued at £150,000.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 6:53 am

GOOG

META

MSFT

Meta Platforms, Inc. (NASDAQ:META) is anticipated to report a significant increase in Q1 earnings, with expectations set at $4.32 per share compared to $2.20 in the previous year. Revenue is also expected to rise to $36.16 billion from $28.64 billion. The company's AI assistant will now feature real-time search results from Google and Bing. Following these announcements, Meta's stock increased by 3% to $496.10. Analysts have recently updated their ratings, with price targets ranging from $550 to $610.

Portfolio Pulse from Avi Kapoor

April 24, 2024 | 6:45 am

ALPMY

Astellas' XTANDI (Enzalutamide) has received approval from the European Commission for use in a new treatment setting for high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer in the EU. This makes XTANDI the first novel hormone therapy available for this condition in the EU. The approval is based on the positive results from the Phase 3 EMBARK study, which demonstrated that XTANDI, alone or in combination with leuprolide, significantly reduced the risk of metastasis or death.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 6:23 am

RKLB

Rocket Lab successfully deployed satellites to two separate orbits for KAIST and NASA, with Electron's Kick Stage completing a final engine burn to lower its altitude and speed up reentry, reducing space junk.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 6:22 am

TSLA

Elon Musk, CEO of Tesla, Inc. (NASDAQ:TSLA), revealed plans for a 'Cybercab' robotaxi fleet during the company's Q1 earnings call, suggesting a dual ownership model akin to Airbnb and Uber. The fleet will include Tesla-owned robotaxis and allow individuals to offer their personal vehicles for rental. Musk's vision, which aligns with his 2019 prediction of a robotaxi network, emphasizes a design inspired by the Cybertruck, featuring angular lines and stainless steel construction. Despite the uncertain timeline for Cybercab's launch, Musk's focus on autonomous vehicles as a key value driver in 2023 is clear, though it has received mixed reactions from analysts.

Portfolio Pulse from Ramakrishnan M

April 24, 2024 | 6:19 am

TSLA

Ross Gerber and Dan Ives have expressed support for Tesla's strategic shift following its Q1 results, despite a revenue drop. Gerber, CEO of Gerber Kawasaki Wealth, is optimistic about Tesla's future, highlighting the difference between being a shareholder and a customer. Dan Ives, an analyst at Wedbush, praised Elon Musk's leadership, especially after Tesla announced plans to accelerate the launch of new, more affordable models. Tesla's shares surged 13.38% in after-hours trading despite a 9% year-over-year revenue drop to $21 billion in Q1, missing estimates.

Portfolio Pulse from Benzinga Neuro

April 24, 2024 | 4:21 am

TSLA

Elon Musk announced during Tesla's Q1 conference call that the Optimus humanoid robot could start external sales by the end of 2025, following limited production in 2024. Musk emphasized Optimus' potential to perform factory tasks and its significant value, potentially exceeding all of Tesla's other ventures. This comes after Tesla reported a 9% decrease in Q1 revenue year-over-year, attributed to lower average selling prices and reduced vehicle deliveries. Musk also noted the cost efficiency of Optimus, estimating initial prices between $25,000 and $30,000.

Portfolio Pulse from Ananya Gairola

April 24, 2024 | 4:14 am

BTCUSD

DOGEUSD

Crypto trader Kevin predicts Dogecoin (DOGE) could outperform Bitcoin (BTC) due to its consolidation in the golden pocket and position above bull market trending moving averages. Dogecoin has already seen a year-to-date gain of 82.8% compared to Bitcoin's 57.5%. Kevin's analysis is supported by Dogecoin's potential Golden Cross and the growing prominence of meme coins in the digital asset space.

Portfolio Pulse from Benzinga Neuro

April 24, 2024 | 3:32 am